Cowen and Company Reaffirms Buy Rating for Dynavax Technologies Corporation (DVAX)

Cowen and Company reissued their buy rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a research note issued to investors on Friday. Cowen and Company currently has a $45.00 target price on the biopharmaceutical company’s stock.

“DVAX announced that it will undergo corporate restructuring, resulting in an ~40%.”,” the firm’s analyst commented.

Several other analysts also recently commented on DVAX. RBC Capital Markets set a $4.00 target price on shares of Dynavax Technologies Corporation and gave the stock a hold rating in a report on Monday, November 14th. Zacks Investment Research downgraded shares of Dynavax Technologies Corporation from a hold rating to a sell rating in a report on Thursday, November 10th. Finally, William Blair reaffirmed an outperform rating and set a $17.00 target price (down previously from $45.00) on shares of Dynavax Technologies Corporation in a report on Saturday, November 19th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation presently has an average rating of Hold and a consensus price target of $20.14.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded down 2.33% on Friday, reaching $4.20. The company had a trading volume of 660,651 shares. The stock’s market capitalization is $161.81 million. The company has a 50 day moving average price of $4.45 and a 200 day moving average price of $10.88. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $29.86.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.15. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $2.44 million. Dynavax Technologies Corporation had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. The business’s quarterly revenue was down 83.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.82) EPS. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post ($3.21) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Community Financial News and is the propert of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international copyright & trademark laws. The legal version of this story can be read at https://www.com-unik.info/2017/01/11/cowen-and-company-reaffirms-buy-rating-for-dynavax-technologies-corporation-dvax.html.

Hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in shares of Dynavax Technologies Corporation during the second quarter worth $107,000. Quantbot Technologies LP purchased a new stake in shares of Dynavax Technologies Corporation during the third quarter worth $102,000. Rathbone Brothers plc purchased a new stake in shares of Dynavax Technologies Corporation during the third quarter worth $105,000. Two Sigma Securities LLC purchased a new stake in shares of Dynavax Technologies Corporation during the third quarter worth $115,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies Corporation during the third quarter worth $125,000. 82.27% of the stock is owned by institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

What are top analysts saying about Dynavax Technologies Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dynavax Technologies Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit